FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3173641617> ?p ?o ?g. }

• W3173641617 endingPage "3583" @default.
• W3173641617 startingPage "3575" @default.
• W3173641617 abstract "COVID-19 has had a calamitous effect on the global community. Despite intense study, the immunologic response to the infection is only partially understood. In addition to older age and ethnicity, patients with comorbidities including obesity, diabetes, hypertension, coronary artery disease, malignancy, renal, and pulmonary disease may experience severe outcomes. Some patients with primary immunodeficiency (PID) and secondary immunodeficiency also appear to be at increased risk from COVID-19. In addition to vulnerability to SARS-CoV-2, patients with PIDs often have chronic pulmonary disease and may not respond to vaccines, which exacerbates their long-term risk. Patients with common variable immunodeficiency disorders, the most frequent symptomatic PID in adults and children, have a spectrum of B- and T-cell defects. It may be possible to stratify their risk for severe COVID-19 based on age, ethnicity, the severity of the T-cell defect, and the presence of other comorbidities. Patients with common variable immunodeficiency disorders and other immunodeficiencies are at risk for Chronic COVID-19, a dangerous stalemate between a suboptimal immune response and SARS-CoV-2. Intra-host viral evolution could result in the rapid emergence of vaccine-resistant mutants and variants of high consequence; it is a public health emergency. Vaccination and prevention of Chronic COVID-19 in immunodeficient patients is therefore of the utmost priority. Having a reliable diagnostic assay for T-cell immunity to SARS-CoV-2 is critical for evaluating responses to vaccines in these patients. New treatments for SARS-CoV-2 such as NZACE2-Pātari are likely to be particularly beneficial for immunodeficient patients, especially those who fail to mount a robust T-cell response to COVID-19 vaccines. COVID-19 has had a calamitous effect on the global community. Despite intense study, the immunologic response to the infection is only partially understood. In addition to older age and ethnicity, patients with comorbidities including obesity, diabetes, hypertension, coronary artery disease, malignancy, renal, and pulmonary disease may experience severe outcomes. Some patients with primary immunodeficiency (PID) and secondary immunodeficiency also appear to be at increased risk from COVID-19. In addition to vulnerability to SARS-CoV-2, patients with PIDs often have chronic pulmonary disease and may not respond to vaccines, which exacerbates their long-term risk. Patients with common variable immunodeficiency disorders, the most frequent symptomatic PID in adults and children, have a spectrum of B- and T-cell defects. It may be possible to stratify their risk for severe COVID-19 based on age, ethnicity, the severity of the T-cell defect, and the presence of other comorbidities. Patients with common variable immunodeficiency disorders and other immunodeficiencies are at risk for Chronic COVID-19, a dangerous stalemate between a suboptimal immune response and SARS-CoV-2. Intra-host viral evolution could result in the rapid emergence of vaccine-resistant mutants and variants of high consequence; it is a public health emergency. Vaccination and prevention of Chronic COVID-19 in immunodeficient patients is therefore of the utmost priority. Having a reliable diagnostic assay for T-cell immunity to SARS-CoV-2 is critical for evaluating responses to vaccines in these patients. New treatments for SARS-CoV-2 such as NZACE2-Pātari are likely to be particularly beneficial for immunodeficient patients, especially those who fail to mount a robust T-cell response to COVID-19 vaccines." @default.
• W3173641617 created "2021-07-05" @default.
• W3173641617 creator A5036776972 @default.
• W3173641617 creator A5044308504 @default.
• W3173641617 creator A5052252680 @default.
• W3173641617 creator A5053399771 @default.
• W3173641617 creator A5075181533 @default.
• W3173641617 creator A5084864189 @default.
• W3173641617 creator A5089073407 @default.
• W3173641617 date "2021-10-01" @default.
• W3173641617 modified "2023-10-17" @default.
• W3173641617 title "Common Variable Immunodeficiency Disorders, T-Cell Responses to SARS-CoV-2 Vaccines, and the Risk of Chronic COVID-19" @default.
• W3173641617 cites W1699352150 @default.
• W3173641617 cites W1966481539 @default.
• W3173641617 cites W1996949486 @default.
• W3173641617 cites W2098542011 @default.
• W3173641617 cites W2235970093 @default.
• W3173641617 cites W2409831280 @default.
• W3173641617 cites W2516638950 @default.
• W3173641617 cites W2572233504 @default.
• W3173641617 cites W2760838426 @default.
• W3173641617 cites W2766419049 @default.
• W3173641617 cites W2789332095 @default.
• W3173641617 cites W2807020737 @default.
• W3173641617 cites W2809153463 @default.
• W3173641617 cites W2892620947 @default.
• W3173641617 cites W2914208637 @default.
• W3173641617 cites W2951865926 @default.
• W3173641617 cites W3001118548 @default.
• W3173641617 cites W3004280078 @default.
• W3173641617 cites W3009885589 @default.
• W3173641617 cites W3009912996 @default.
• W3173641617 cites W3011537081 @default.
• W3173641617 cites W3011871622 @default.
• W3173641617 cites W3014294089 @default.
• W3173641617 cites W3018910405 @default.
• W3173641617 cites W3021578896 @default.
• W3173641617 cites W3023172625 @default.
• W3173641617 cites W3025203498 @default.
• W3173641617 cites W3025490592 @default.
• W3173641617 cites W3030748957 @default.
• W3173641617 cites W3033813936 @default.
• W3173641617 cites W3037718428 @default.
• W3173641617 cites W3039901154 @default.
• W3173641617 cites W3040727634 @default.
• W3173641617 cites W3042833857 @default.
• W3173641617 cites W3043722389 @default.
• W3173641617 cites W3044947870 @default.
• W3173641617 cites W3045130610 @default.
• W3173641617 cites W3046194290 @default.
• W3173641617 cites W3046369848 @default.
• W3173641617 cites W3047135833 @default.
• W3173641617 cites W3048620154 @default.
• W3173641617 cites W3048775784 @default.
• W3173641617 cites W3048999632 @default.
• W3173641617 cites W3081710107 @default.
• W3173641617 cites W3082438395 @default.
• W3173641617 cites W3084879098 @default.
• W3173641617 cites W3085031248 @default.
• W3173641617 cites W3088256443 @default.
• W3173641617 cites W3088841124 @default.
• W3173641617 cites W3089890285 @default.
• W3173641617 cites W3090209951 @default.
• W3173641617 cites W3094870207 @default.
• W3173641617 cites W3096064145 @default.
• W3173641617 cites W3102798166 @default.
• W3173641617 cites W3103466171 @default.
• W3173641617 cites W3104396521 @default.
• W3173641617 cites W3104536464 @default.
• W3173641617 cites W3107730772 @default.
• W3173641617 cites W3108495775 @default.
• W3173641617 cites W3108668552 @default.
• W3173641617 cites W3108728530 @default.
• W3173641617 cites W3109136263 @default.
• W3173641617 cites W3109911722 @default.
• W3173641617 cites W3110773787 @default.
• W3173641617 cites W3112389441 @default.
• W3173641617 cites W3117059389 @default.
• W3173641617 cites W3117730334 @default.
• W3173641617 cites W3120305145 @default.
• W3173641617 cites W3120327534 @default.
• W3173641617 cites W3120346150 @default.
• W3173641617 cites W3120382576 @default.
• W3173641617 cites W3120714204 @default.
• W3173641617 cites W3121008609 @default.
• W3173641617 cites W3121193681 @default.
• W3173641617 cites W3123967880 @default.
• W3173641617 cites W3125067742 @default.
• W3173641617 cites W3127885005 @default.
• W3173641617 cites W3128154910 @default.
• W3173641617 cites W3128920295 @default.
• W3173641617 cites W3129499258 @default.
• W3173641617 cites W3131534222 @default.
• W3173641617 cites W3131688063 @default.
• W3173641617 cites W3132912063 @default.
• W3173641617 cites W3133663934 @default.
• W3173641617 cites W3134591945 @default.
• W3173641617 cites W3135033031 @default.

• next